Healthlink Capital
VC Fund
Healthlink Capital is a VC fund focused on Biotechnology and Medical. Healthlink Capital
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Healthlink Capital invests in
Stages Healthlink Capital invests in
Countries Healthlink Capital invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Health Care 2 (50%)
- Genetics 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series A 2 (50%)
- Series B 2 (50%)
Country
- United States 2 (50%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lyndra Therapeutics
|
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $60.9M / Series B / Feb 11, 2019 | |
Congenica
|
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of geneticdisease for patients.It was founded in 2013 and headquartered in Cambridge, Cambridgeshire. | Series B / Apr 27, 2017 | |
|
Lyndra Therapeutics
|
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximizeglobal health impact and lower overall healthcare costs. | $23M / Series A / Apr 13, 2017 | |
Sapience Therapeutics
|
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $22.5M / Series A / Jul 12, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Healthlink Capital invest in?
Healthlink Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Healthlink Capital last invest?
The most recent investment recorded for Healthlink Capital closed in Feb 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
